Hologic, Inc. (NASDAQ:HOLX) Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. raised its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 62.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,315 shares of the medical equipment provider's stock after purchasing an additional 5,908 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in Hologic were worth $1,104,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brooklyn Investment Group boosted its stake in shares of Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC grew its stake in Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after acquiring an additional 169 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after purchasing an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc grew its position in shares of Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after purchasing an additional 200 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Down 0.7 %

NASDAQ:HOLX traded down $0.41 during trading hours on Wednesday, reaching $57.95. The company's stock had a trading volume of 421,031 shares, compared to its average volume of 1,966,059. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market capitalization of $13.00 billion, a P/E ratio of 18.27, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The stock has a 50 day moving average price of $60.78 and a two-hundred day moving average price of $69.69. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research analyst reports. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.